SPR-based fragment screening with neurotensin receptor 1 generates novel small molecule ligands

• Sylwia Huber ,

  * E-mail: sylwia.huber@roche.com (SH); michael.hennig@leadxpro.com (MH)

  Affiliation Roche Innovation Center Basel, Pharmaceutical Research and Early Development, Basel, Switzerland

  ⨯
• Fabio Casagrande,

  Affiliation Roche Innovation Center Basel, Pharmaceutical Research and Early Development, Basel, Switzerland

  ⨯
• Melanie N. Hug,

  Affiliation Roche Innovation Center Basel, Pharmaceutical Research and Early Development, Basel, Switzerland

  ⨯
• Lisha Wang,

  Affiliation Roche Innovation Center Basel, Pharmaceutical Research and Early Development, Basel, Switzerland

  ⨯
• Philipp Heine,

  Affiliation Department of Biochemistry, University of Zurich, Zurich, Switzerland

  ⨯
• Lutz Kummer,

  Current address: G7 Therapeutics AG, Schlieren, Switzerland

  Affiliation Department of Biochemistry, University of Zurich, Zurich, Switzerland

  ⨯
• Andreas Plückthun,

  Affiliation Department of Biochemistry, University of Zurich, Zurich, Switzerland

  ⨯
• Michael Hennig

  * E-mail: sylwia.huber@roche.com (SH); michael.hennig@leadxpro.com (MH)

  Current address: leadXpro AG, PARK INNOVAARE, Villigen, Switzerland

  Affiliation Roche Innovation Center Basel, Pharmaceutical Research and Early Development, Basel, Switzerland

  ⨯